Gimeno-García Antonio Z, Ramírez Francisco, Gonzalo Victòria, Balaguer Francesc, Petit Anna, Pellisé Maria, Llach Josep, Bordas Josep M, Piqué Josep M, Castells Antoni
Servicio de Gastroenterología, Institut de Malalties Digestives, Hospital Clínic, Universitat de Barcelona, Barcelona, España.
Gastroenterol Hepatol. 2007 Apr;30(4):207-11. doi: 10.1157/13100586.
Patients with advanced adenomas (AA) have a high risk of developing advanced colorectal neoplasms. Therefore, shorter monitoring intervals have been recommended in this patient subgroup. High grade dysplasia (HGD) is the main marker of cancer transformation. However, its predictive value for developing advanced neoplams in patients with advanced adenoma is unknown.
To investigate if HGD increases the risk for developing advanced neoplasms in patients with AA.
Between January 1996 and December 1997 every patient with an AA endoscopically resected were considered for inclusion. Patients with a history of colorectal cancer (CRC), inflammatory bowel disease, familial adenomatous polyposis or patients who met the Amsterdam criteria, and those without colonoscopic monitoring were excluded. We assessed the development of advanced neoplasms during the study period.
71 patients were included and classified into 2 groups, depending on the presence (n = 49) or lack (n = 22) of HGD in the initial colonoscopy. The probability of developing advanced neoplasms (log rank, p = 0.47; Breslow, p = 0.58) or AA with HGD (log rank, p = 0.47; Breslow, p = 0.53) in the study period was similar between both groups. The number of metachronic polyps (p = 0.67), adenomas (p = 0.73), AA (p = 0.93) and AA with HGD (p = 0.88) was also similar.
The risk of developing advanced neoplasms is not different between AA with HGD and those with other characteristics of AA (villous pattern and larger than 1 cm). Therefore, changes in monitoring intervals are not warranted.
晚期腺瘤(AA)患者发生晚期结直肠肿瘤的风险较高。因此,建议对该患者亚组缩短监测间隔。高级别上皮内瘤变(HGD)是癌症转化的主要标志物。然而,其对晚期腺瘤患者发生晚期肿瘤的预测价值尚不清楚。
研究HGD是否会增加AA患者发生晚期肿瘤的风险。
纳入1996年1月至1997年12月间每例经内镜切除AA的患者。排除有结直肠癌(CRC)、炎症性肠病、家族性腺瘤性息肉病病史或符合阿姆斯特丹标准的患者,以及未接受结肠镜监测的患者。我们评估了研究期间晚期肿瘤的发生情况。
纳入71例患者,根据初次结肠镜检查时是否存在HGD(n = 49)或不存在HGD(n = 22)分为两组。两组在研究期间发生晚期肿瘤(对数秩检验,p = 0.47;Breslow检验,p = 0.58)或伴有HGD的AA(对数秩检验,p = 0.47;Breslow检验,p = 0.53)的概率相似。异时性息肉(p = 0.67)、腺瘤(p = 0.73)、AA(p = 0.93)和伴有HGD的AA(p = 0.88)的数量也相似。
伴有HGD的AA与具有其他AA特征(绒毛状形态且直径大于1 cm)的患者发生晚期肿瘤的风险无差异。因此,无需改变监测间隔。